“HepaRegeniX develops a unique, therapeutic concept for the treatment of acute and chronic liver diseases. It is based on unlocking the regenerative capacity of liver cells, even in severely diseased livers.”
Dr. Michael Lutz
CEO
Location: Germany, Baden-Württemberg, Ulm
Total raised: $12.53M
Investors 1
| Date | Name | Website |
| - | Coparion | coparion.v... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.01.2020 | Series B | $12.53M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 30.03.2022 | HepaRegeniX Appoints Elias Papatheodorou as New Chairman of ... | TUBINGEN, GERMANY / ACCESSWIRE / March 30, 2022 / HepaRegeniX GmbH, a clinical stage company develop... | accesswire... |
| 04.11.2021 | HepaRegeniX to present key results on MKK4 inhibitors and th... | DGAP-News: HepaRegeniX GmbH / Key word(s): Conference/Alliance HepaRegeniX to present key results o... | marketscre... |
| 20.10.2021 | HepaRegeniX GmbH : initiates a preclinical collaboration wit... | DGAP-News: HepaRegeniX GmbH / Key word(s): Alliance HepaRegeniX initiates a preclinical collaborati... | marketscre... |
| 24.01.2020 | HepaRegeniX Closes Over €11M Series B Financing round | HepaRegeniX, a Tübingen, Germany-based preclinical stage company developing a novel therapy for the ... | finsmes.co... |
| 06.01.2017 | HepaRegeniX Raises €9M in Series A Financing | HepaRegeniX GmbH, a biotech company developing innovative treatments for liver diseases, completed a... | finsmes.co... |
| - | HepaRegeniX GmbH secures Series B Financing in excess of €11... | January 21, 2020 Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and... | htgf.de/en... |